Astellas Pharma has shared promising early results from its ongoing OPTION-VMS study. The study, which includes over 900 women aged 40–75 experiencing menopause symptoms, found that the medication fezolinetant significantly reduces hot flashes and night sweats. Participants also reported better sleep, improved work performance, and enhanced daily functioning after 4, 8, and 12 weeks of treatment. These results will be presented at The Menopause Society’s 2025 Annual Meeting in Orlando, Florida. Genevieve Neal-Perry, Chair of the Department of Obstetrics and Gynecology at UNC School of Medicine, noted that the findings support fezolinetant as an effective treatment for menopause symptoms. Women in the study saw improvements in sleep quality, work productivity, and overall daily life as early as four weeks into the treatment. The study also measured sleep improvements using both self-reported assessments and wearable devices, showing significant gains in sleep efficiency and reduced wakefulness during the night. Shayna Mancuso, Head of US Medical Affairs for Women’s Health at Astellas, emphasized the company’s dedication to understanding fezolinetant’s benefits beyond initial clinical trials. She highlighted that untreated menopause symptoms like hot flashes and night sweats can greatly disrupt sleep and daily activities. The study reported minimal side effects, consistent with previous findings, with no new safety concerns identified. Complete results will be available after the final analysis.